Rebecca Cheng

489 total citations
28 papers, 340 citations indexed

About

Rebecca Cheng is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Rebecca Cheng has authored 28 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 6 papers in Surgery. Recurrent topics in Rebecca Cheng's work include Gastric Cancer Management and Outcomes (12 papers), Colorectal Cancer Treatments and Studies (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Rebecca Cheng is often cited by papers focused on Gastric Cancer Management and Outcomes (12 papers), Colorectal Cancer Treatments and Studies (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Rebecca Cheng collaborates with scholars based in Taiwan, South Korea and United States. Rebecca Cheng's co-authors include Mauro Orlando, Andy Yan, Steven J. E. Wilton, Roberto Carlesi, Winnie Yeo, Yoon‐Koo Kang, Li‐Tzong Chen, Do‐Youn Oh, Kun‐Huei Yeh and Y. Choi and has published in prestigious journals such as Journal of Clinical Oncology, Optics Express and Oncotarget.

In The Last Decade

Rebecca Cheng

28 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca Cheng Taiwan 12 188 149 68 58 53 28 340
Ariel E. Birnbaum United States 8 119 0.6× 118 0.8× 60 0.9× 60 1.0× 13 0.2× 25 284
Yuqian Huang China 13 120 0.6× 179 1.2× 81 1.2× 119 2.1× 5 0.1× 33 490
Hong-Gang Qian China 14 107 0.6× 186 1.2× 133 2.0× 113 1.9× 4 0.1× 31 447
Quan Xu China 11 94 0.5× 68 0.5× 111 1.6× 56 1.0× 4 0.1× 28 258
Ying Lv China 11 70 0.4× 167 1.1× 127 1.9× 77 1.3× 7 0.1× 26 360
Woo Gyeong Kim South Korea 11 84 0.4× 134 0.9× 49 0.7× 68 1.2× 7 0.1× 36 330
Shinji Endo Japan 12 96 0.5× 130 0.9× 93 1.4× 109 1.9× 3 0.1× 28 350
Γεώργιος Αντωνίου United Kingdom 11 172 0.9× 140 0.9× 127 1.9× 62 1.1× 4 0.1× 31 371
Daniele Marinelli Italy 10 98 0.5× 132 0.9× 57 0.8× 104 1.8× 12 0.2× 35 330

Countries citing papers authored by Rebecca Cheng

Since Specialization
Citations

This map shows the geographic impact of Rebecca Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Cheng more than expected).

Fields of papers citing papers by Rebecca Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Cheng. The network helps show where Rebecca Cheng may publish in the future.

Co-authorship network of co-authors of Rebecca Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Cheng. A scholar is included among the top collaborators of Rebecca Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Cheng. Rebecca Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rajappa, Senthil, et al.. (2022). Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. World Journal of Hepatology. 14(6). 1074–1086. 1 indexed citations
2.
Chen, Ming‐Huang, Sheng‐Nan Lu, Chien‐Hung Chen, et al.. (2021). How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers. 13(14). 3536–3536. 7 indexed citations
3.
Lu, Yen‐Shen, Winnie Yeo, Yoon Sim Yap, et al.. (2021). An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. Targeted Oncology. 16(6). 701–741. 7 indexed citations
4.
5.
Lin, Chia‐Chi, Tsai‐Sheng Yang, Chia-Jui Yen, et al.. (2020). Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. The Oncologist. 25(12). e1921–e1929. 4 indexed citations
6.
7.
Reck, Martin, Marina Chiara Garassino, Martina Imbimbo, et al.. (2018). Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 120. 62–69. 23 indexed citations
8.
Chen, Li‐Tzong, Do‐Youn Oh, Min‐Hee Ryu, et al.. (2017). Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Research and Treatment. 49(4). 851–868. 51 indexed citations
9.
Hong, Jihyung, et al.. (2017). The economic burden of advanced gastric cancer in Taiwan. BMC Health Services Research. 17(1). 663–663. 14 indexed citations
10.
Muro, Kei, Y. Choi, G. Bodoky, et al.. (2017). Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.. Journal of Clinical Oncology. 35(4_suppl). 3–3. 3 indexed citations
11.
Kim, Tae You, Chia-Jui Yen, Salah‐Eddin Al‐Batran, et al.. (2017). Exposure–response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 21(2). 276–284. 8 indexed citations
12.
Carter, Gebra Cuyún, Anna Kaltenboeck, Jasmina I. Ivanova, et al.. (2016). Treatment patterns in patients with advanced gastric cancer in Taiwan. Asia-Pacific Journal of Clinical Oncology. 13(3). 185–194. 11 indexed citations
13.
Carter, Gebra Cuyún, Anna Kaltenboeck, Jasmina I. Ivanova, et al.. (2016). Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea. Cancer Research and Treatment. 49(3). 578–587. 21 indexed citations
14.
Park, Joon Oh, Baek‐Yeol Ryoo, Chia-Jui Yen, et al.. (2016). Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 7(46). 75482–75491. 12 indexed citations
15.
Lee, Dae Ho, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, & Mauro Orlando. (2015). Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned. Cancer Research and Treatment. 47(4). 549–554. 8 indexed citations
16.
Muro, Kei, Sang Cheul Oh, Yasuhiro Shimada, et al.. (2015). Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of Gastroenterology and Hepatology. 31(3). 581–589. 31 indexed citations
17.
Yang, James Chih‐Hsin, Myung‐Ju Ahn, Kazuhiko Nakagawa, et al.. (2014). Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. Cancer Research and Treatment. 47(3). 424–435. 2 indexed citations
18.
Pereira, José Rodrigues, Rebecca Cheng, Mauro Orlando, Joo-Hang Kim, & Helen Barraclough. (2013). Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Drugs in R&D. 13(4). 289–296. 16 indexed citations
19.
Cheng, Rebecca, et al.. (2003). Con la solidez del cemento. 8(2). 68–75. 1 indexed citations
20.
Yan, Andy, Rebecca Cheng, & Steven J. E. Wilton. (2002). On the sensitivity of FPGA architectural conclusions to experimental assumptions, tools, and techniques. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ariel E. Birnbaum Breakdown of academic impact, for papers by Yuqian Huang Breakdown of academic impact, for papers by Hong-Gang Qian Breakdown of academic impact, for papers by Quan Xu Breakdown of academic impact, for papers by Ying Lv Breakdown of academic impact, for papers by Woo Gyeong Kim Breakdown of academic impact, for papers by Shinji Endo Breakdown of academic impact, for papers by Γεώργιος Αντωνίου Breakdown of academic impact, for papers by Daniele Marinelli
Rankless by CCL
2026